THOUSAND OAKS – Amgen (AMGN), a leader in biotechnology worldwide, stated that it will invest over $600 million to construct a brand-new, cutting-edge science and innovation center at its global headquarters in Thousand Oaks, California. In addition to strengthening the company’s commitment to promoting scientific research and development locally, this action is expected to generate hundreds of jobs in the United States.
The new building is intended to serve as a center for interdisciplinary cooperation, bringing scientists, engineers, and researchers together to speed up the development of next-generation treatments. With its sophisticated automation and digital capabilities, the center will give Amgen’s scientific teams the resources and setting they need to spur innovation in the biotechnology industry.
Read More: Amgen Announces $900 Million Worth Expansion of Manufacturing Facility in the US
In the third quarter of 2025, work on the new facility is expected to start. This investment is a component of Amgen’s broader plan to grow its business in the United States, which has included more than $40 billion in R&D and production since 2017. A $1 billion investment to construct a second manufacturing plant in Holly Springs, North Carolina, and a $900 million expansion of the company’s Central Ohio site are also significant domestic expenditures.
At Amgen, we’re continuing to invest in the future of American science and innovation. This new center will empower our scientists with the tools and collaborative environment they need to shape the next era of scientific discovery and advance medicines that improve human health.
Robert A. Bradway
Read More: Amgen Reports Strong Q1 2025 Results Driven by Robust Volume Growth and Key Product Performance
Since its establishment more than 45 years ago, Amgen has been a vital component of the Thousand Oaks neighborhood, which is a part of the larger Los Angeles area. The company’s research capacity will be improved by this most recent investment, which will also greatly boost the local economy by creating jobs.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Amgen is renowned for its efforts in creating cutting-edge medications for people suffering from life-threatening conditions. For more than 40 years, the firm has led the biotechnology sector, using technology and human genetic data to develop a wide range of medications to treat conditions like cancer, heart disease, osteoporosis, inflammatory illnesses, and rare diseases.
Last Modified:
